Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NASDAQ Clean Edge Green Energy UCITS ETF 15.10.2026 QCLN.LN IE00BDBRT036 1,900,002.00 USD  32,712,399.30   17.217  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones Internet UCITS ETF 15.10.2026 FDNU IE00BG0SSC32 1,275,002.00 USD  51,708,101.42   40.555  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Cybersecurity UCITS ETF 15.10.2026 NQCYBREN IE00BF16M727 30,389,755.00 USD 1,967,037,566.74   64.727  ...
-

From PV to ET to PMF, PharmaEssentia Has Come A Long Way in Fighting Diseases

TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials and overseas investments, as it seeks to bring its Taiwan-developed innovative new drug to more international markets. Founded in Taiwan in 2003 by scientist Dr. Ko-Chung Lin (林國鐘), with a commitment to developing innovative treatments for patients worldwide, PharmaEssentia has developed integrated capabi...
-

دبي للثقافة: دبي الأولى عالمياً في استقطاب مشاريع الاستثمار الأجنبي المباشر الجديدة في الصناعات الثقافية والإبداعية خلال عام 2025

دبي، الإمارات العربية المتحدة--(BUSINESS WIRE)--Dubai Culture: Dubai Ranks First Globally in Attracting New FDI Projects in Cultural and Creative Industries in 2025...
-

LibertyStream Provides Commercial Update

DALLAS--(BUSINESS WIRE)--LibertyStream Infrastructure Partners Inc. (TSXV: LIB | OTCQB: VLTLF | FSE: I2D) (“LibertyStream” or the “Company”) today provided an operational and commercial update. Since May 2026, LibertyStream has extracted and refined lithium carbonate at its Freedom Launchpad facility in Texas, which runs the full Freedom 1 process flow. A number of prospective end-user customers have validated this product or are completing their evaluation. Highlights Offtake discussions with...
-

NATIXIS UK Regulatory Announcement: Form 8.3 Rotork plc

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust NYSE Arca Biotechnology UCITS ETF 15.10.2026 FBTU.LN IE00BL0L0H60 550,002.00 USD 18,077,945.88 32.869  ...
-

From Taiwan to the World: PharmaEssentia Builds a Scientist-Led, Fully Integrated Global Biopharmaceutical Company with Patients at Its Core

TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials and overseas investments, as it seeks to bring its Taiwan-developed innovative new drug to more international markets. Founded in Taiwan in 2003 by scientist Dr. Ko-Chung Lin (林國鐘), with a commitment to developing innovative treatments for patients worldwide, PharmaEssentia has developed integrated capabi...
-

From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments

TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials and overseas investments, as it seeks to bring its Taiwan-developed innovative new drug to more international markets. Founded in Taiwan in 2003 by scientist Dr. Ko-Chung Lin (林國鐘), with a commitment to developing innovative treatments for patients worldwide, PharmaEssentia has developed integrated capabi...